We are seeking a highly motivated researcher to work on developing a new treatment for the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. This disease can affect joints, lungs, kidneys, skin and other tissues and occurs most often in older adults. It is characterized by antibodies that bind in particular to the proteins myeloperoxidase (MPO) proteinase 3 which are found in neutrophils and monocytes. The antibodies are thought to play a key role in causing disease. This study will define whether a therapeutic agent is effective in reducing disease onset and/or development. We plan to test this using an established preclinical model. We have discovered some highly novel effects of ANCA on human monocytes and evidence to suggest the drug will modify this effect with relevance for disease. Therefore in vitro experiments will also be performed to investigate this further.
Candidates must have a PhD (or equivalent) in immunology, or a related discipline. Those who have submitted their thesis and are awaiting award of their PhDs may be considered.
The post is based within Dr Michael Robson's laboratory within the MRC Centre for Transplantation, King's College London. The post is funded by a Medical Research Council grant for 3 years and is a collaborative project with a commercial partner who have developed the drug. This full-time post will be fixed term contract for 36 months.
For more infomration on the two positions and to apply online, please visit:
The closing date is 13 December 2017 and interviews will be held 18 December 2017 and can be via Skype for candidates outside the UK.